BRPI0406772A - Composto, processos para preparar um éter fenìlico de aminoácido e o composto, composição farmacêutica, métodos para reduzir glicose, ácidos graxos livres, colesterol, e os nìveis de triglicerìdeo no plasma, para tratar obesidade, doenças autoimunes, inflamação, doença iimunológica, e um distúrbio associado com resistência a insulina, e, intermediário - Google Patents

Composto, processos para preparar um éter fenìlico de aminoácido e o composto, composição farmacêutica, métodos para reduzir glicose, ácidos graxos livres, colesterol, e os nìveis de triglicerìdeo no plasma, para tratar obesidade, doenças autoimunes, inflamação, doença iimunológica, e um distúrbio associado com resistência a insulina, e, intermediário

Info

Publication number
BRPI0406772A
BRPI0406772A BR0406772-0A BRPI0406772A BRPI0406772A BR PI0406772 A BRPI0406772 A BR PI0406772A BR PI0406772 A BRPI0406772 A BR PI0406772A BR PI0406772 A BRPI0406772 A BR PI0406772A
Authority
BR
Brazil
Prior art keywords
compound
inflammation
amino acid
cholesterol
preparing
Prior art date
Application number
BR0406772-0A
Other languages
English (en)
Inventor
Bishwajit Nag
Abhijeet Nag
Debendranath Dey
Shiv Kumar Agarwal
Original Assignee
Bexel Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bexel Pharmaceuticals Inc filed Critical Bexel Pharmaceuticals Inc
Publication of BRPI0406772A publication Critical patent/BRPI0406772A/pt
Publication of BRPI0406772B1 publication Critical patent/BRPI0406772B1/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/34—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D263/44—Two oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/421—1,3-Oxazoles, e.g. pemoline, trimethadione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/34—Oxygen atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Emergency Medicine (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Neurology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurosurgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Transplantation (AREA)
  • Cardiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

"COMPOSTO, PROCESSOS PARA PREPARAR UM éTER FENìLICO DE AMINOáCIDO E O COMPOSTO, COMPOSIçãO FARMACêUTICA, MéTODOS PARA REDUZIR GLICOSE, áCIDOS GRAXOS LIVRES, COLESTEROL, E OS NìVEIS DE TRIGLICERìDEO NO PLASMA, PARA TRATAR OBESIDADE, DOENçAS AUTOIMUNES, INFLAMAçãO, DOENçA IMUNOLóGICA, E UM DISTúRBIO ASSOCIADO COM RESISTêNCIA A INSULINA E INTERMEDIáRIO". Novos éteres fenílicos de aminoácido são fornecidos, os quais apresentam atividade para o tratamento de doenças imonológicas, inflamação, obesidade, hiperlipidemia, hipertensão, doenças neurológicas e diabete.
BRPI0406772A 2003-01-17 2004-01-13 composto, processos para preparar um éter fenílico de aminoácido e o composto, composição farmacêutica, uso de um composto, e, intermediário BRPI0406772B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US44077203P 2003-01-17 2003-01-17
US10/356,113 US6794401B2 (en) 2003-01-17 2003-01-31 Amino acid phenoxy ethers
PCT/US2004/000790 WO2004066964A2 (en) 2003-01-17 2004-01-13 Amino acid phenoxy ethers

Publications (2)

Publication Number Publication Date
BRPI0406772A true BRPI0406772A (pt) 2005-12-27
BRPI0406772B1 BRPI0406772B1 (pt) 2016-08-23

Family

ID=32716922

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0406772A BRPI0406772B1 (pt) 2003-01-17 2004-01-13 composto, processos para preparar um éter fenílico de aminoácido e o composto, composição farmacêutica, uso de um composto, e, intermediário

Country Status (20)

Country Link
US (2) US6794401B2 (pt)
EP (1) EP1583529B9 (pt)
JP (1) JP4833072B2 (pt)
KR (1) KR101085315B1 (pt)
AT (1) ATE532510T1 (pt)
AU (1) AU2004207449A1 (pt)
BR (1) BRPI0406772B1 (pt)
CA (1) CA2513496C (pt)
CY (1) CY1112673T1 (pt)
DK (1) DK1583529T3 (pt)
EA (1) EA200501078A1 (pt)
ES (1) ES2374724T3 (pt)
MA (1) MA27658A1 (pt)
MX (1) MXPA05007684A (pt)
NO (1) NO330984B1 (pt)
NZ (1) NZ541328A (pt)
PT (1) PT1583529E (pt)
SI (1) SI1583529T1 (pt)
TW (1) TWI325420B (pt)
WO (1) WO2004066964A2 (pt)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7521465B2 (en) * 2003-01-17 2009-04-21 Bexel Pharmaceuticals, Inc. Diphenyl ether derivatives
US7781464B2 (en) * 2003-01-17 2010-08-24 Bexel Pharmaceuticals, Inc. Heterocyclic diphenyl ethers
US7087576B2 (en) * 2003-10-07 2006-08-08 Bexel Pharmaceuticals, Inc. Dipeptide phenyl ethers
US7592486B2 (en) * 2004-09-16 2009-09-22 Board Of Regents Of The University Of Nebraska Anhydrous fluoride salts and reagents and methods for their production
EP1858845A2 (en) * 2005-03-18 2007-11-28 Orchid Chemicals and Pharmaceuticals Limited Novel tyrosine derivatives
US20090203744A1 (en) * 2005-07-29 2009-08-13 Pande Y Surendrakumar Satyanarayan Novel pyridine derivatives
EP2066800A2 (en) * 2006-08-04 2009-06-10 Decode Genetics EHF Aryl amino acid derivatives as inhibitors of lta4h (leukotriene a4 hydrolase) for treating inflammation
EP2170306A1 (en) * 2007-06-26 2010-04-07 Lexicon Pharmaceuticals, Inc. Methods of treating serotonin-mediated diseases and disorders
US7875622B2 (en) 2007-07-11 2011-01-25 Lexicon Pharmaceuticals, Inc. Methods and compositions for treating pulmonary hypertension and related diseases and disorders
WO2009030968A1 (en) * 2007-09-05 2009-03-12 Orchid Research Laboratories Limited Mao a inhibitors with a diphenyl ether-substructure.
WO2009143041A1 (en) 2008-05-20 2009-11-26 Merck & Co., Inc. Efficient production of heterologous proteins using mannosyl transferase inhibitors
CN103108634B (zh) 2010-07-28 2015-08-12 幽兰化学医药有限公司 用于治疗肝病、肺病、糖尿病并发症和心血管疾病的二苯醚化合物
US9056862B2 (en) 2011-05-10 2015-06-16 National University Corporation Kobe University Thioxothiazolidine derivative having Ras function inhibitory effect

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020049240A1 (en) * 1994-12-19 2002-04-25 Beecham Group P.1.C. Novel compounds
US5166137A (en) 1991-03-27 1992-11-24 Nobipols Forskningsstiftelse Guluronic acid polymers and use of same for inhibition of cytokine production
US5441971A (en) * 1991-04-11 1995-08-15 The Upjohn Company Thiazolidinedione derivatives, production and use thereof
ES2139633T3 (es) * 1992-08-31 2000-02-16 Sankyo Co Derivados de oxazolidina con propiedades anti-diabetica y anti-obesidad, su preparacion y su utilizacion terapeutica.
TW268952B (pt) * 1993-02-26 1996-01-21 Takeda Pharm Industry Co Ltd
NZ274346A (en) * 1993-09-15 1997-06-24 Sankyo Co Use of various thiazolidine-2,4-dione and oxazolidine-2,4-dione derivatives to prevent or delay onset of non-insulin dependent diabetes mellitus
US5527546A (en) 1994-08-10 1996-06-18 Bayer Corporation Human interleukin 6 inhibitor
DE4432101A1 (de) * 1994-09-09 1996-03-14 Hoechst Ag Aminosäure-substituierte Benzoylguanidine, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament
ATE271128T1 (de) 1995-05-11 2004-07-15 Applied Research Systems Inhibitoren der il-6 aktivitaet
IL118474A (en) * 1995-06-01 2001-08-08 Sankyo Co Benzimideol derivatives and pharmaceutical preparations containing them
TWI238064B (en) * 1995-06-20 2005-08-21 Takeda Chemical Industries Ltd A pharmaceutical composition for prophylaxis and treatment of diabetes
TW577875B (en) * 1997-01-31 2004-03-01 Shionogi & Co Pyrrolidine derivatives with inhibitory activity for phospholipase A2
JPH11124331A (ja) * 1997-08-21 1999-05-11 Takeda Chem Ind Ltd 抗炎症剤
US6331633B1 (en) 1998-05-08 2001-12-18 Calyx Therapeutics Inc. Heterocyclic analogs of diphenylethylene compounds
US6699896B1 (en) * 1998-05-12 2004-03-02 Wyeth Oxazole-aryl-carboxylic acids useful in the treatment of insulin resistance and hyperglycemia
WO1999064417A2 (en) * 1998-06-05 1999-12-16 Astrazeneca Ab Oxazolidinone derivatives, process for their preparation and pharmaceutical compositions containing them
US6664281B1 (en) * 1998-08-27 2003-12-16 Ono Pharmaceutical Co., Ltd. Carboxylic acid derivatives and drugs containing the same as the active ingredient
YU72201A (sh) 1999-04-28 2005-07-19 Aventis Pharma Deutschland Gmbh. Derivati di-aril kiseline kao ppar receptorski ligandi
TWI284533B (en) * 1999-05-24 2007-08-01 Sankyo Co Pharmaceutical composition for treating hyperglycemia, impaired glucose tolerance, diabetes complications and for improving insulin resistant
KR20010099634A (ko) 1999-07-01 2001-11-09 할리 켈빈 비. 텔로머라제 저해제 및 그 사용 방법
CN1155586C (zh) * 1999-08-23 2004-06-30 杏林制药株式会社 取代的苄基噻唑烷-2,4-二酮衍生物
JP2003508391A (ja) * 1999-08-31 2003-03-04 マキシア・ファーマシューティカルズ・インコーポレイテッド ベンジリデン−チアゾリジンジオン類およびアナログ類ならびに糖尿病の治療におけるその使用
JP2001199888A (ja) * 2000-01-24 2001-07-24 Fujimoto Brothers:Kk 糖尿病治療剤
JP2001294537A (ja) * 2000-02-10 2001-10-23 Takeda Chem Ind Ltd 併用医薬
EP1148054B1 (en) 2000-04-21 2005-11-23 Pfizer Products Inc. Thyroid receptor ligands
US6680387B2 (en) * 2000-04-24 2004-01-20 Aryx Therapeutics Materials and methods for the treatment of diabetes, hyperlipidemia, hypercholesterolemia, and atherosclerosis

Also Published As

Publication number Publication date
ATE532510T1 (de) 2011-11-15
DK1583529T3 (da) 2012-01-23
WO2004066964A2 (en) 2004-08-12
NO330984B1 (no) 2011-08-29
JP2007501288A (ja) 2007-01-25
TW200418792A (en) 2004-10-01
EP1583529B9 (en) 2012-04-04
MA27658A1 (fr) 2005-12-01
MXPA05007684A (es) 2006-03-10
BRPI0406772B1 (pt) 2016-08-23
NO20053714D0 (no) 2005-08-01
EA200501078A1 (ru) 2006-02-24
NZ541328A (en) 2008-11-28
US20040142991A1 (en) 2004-07-22
WO2004066964A9 (en) 2004-09-02
SI1583529T1 (sl) 2012-02-29
KR20050092764A (ko) 2005-09-22
ES2374724T3 (es) 2012-02-21
JP4833072B2 (ja) 2011-12-07
PT1583529E (pt) 2012-02-13
TWI325420B (en) 2010-06-01
CA2513496C (en) 2013-05-14
EP1583529B1 (en) 2011-11-09
CA2513496A1 (en) 2004-08-12
AU2004207449A1 (en) 2004-08-12
US20050096366A1 (en) 2005-05-05
WO2004066964A3 (en) 2005-02-24
CY1112673T1 (el) 2016-02-10
EP1583529A2 (en) 2005-10-12
NO20053714L (no) 2005-10-11
KR101085315B1 (ko) 2011-11-22
EP1583529A4 (en) 2007-07-04
US6794401B2 (en) 2004-09-21

Similar Documents

Publication Publication Date Title
BRPI0406772A (pt) Composto, processos para preparar um éter fenìlico de aminoácido e o composto, composição farmacêutica, métodos para reduzir glicose, ácidos graxos livres, colesterol, e os nìveis de triglicerìdeo no plasma, para tratar obesidade, doenças autoimunes, inflamação, doença iimunológica, e um distúrbio associado com resistência a insulina, e, intermediário
Pan et al. Curcumin improves glycolipid metabolism through regulating peroxisome proliferator activated receptor γ signalling pathway in high-fat diet-induced obese mice and 3T3-L1 adipocytes
EA201300550A1 (ru) Фармацевтическая композиция, способы лечения и их применение
EP3124045A3 (en) Treatment of il-1 beta related diseases
WO2006093348A3 (en) Method and composition for treating peripheral vascular diseases
BR0314760A (pt) Compostos orgânicos
BRPI0711908B8 (pt) anticorpo anti-interleucina-18 humanizado, composição farmacêutica, uso de um anticorpo anti-interleucina 18, e, método de produção de um anticorpo.
EA201100910A1 (ru) Лечение воспалительных заболеваний кишечника бета-дефенсинами млекопитающих
WO2007073178A3 (en) Composition comprising polyunsaturated fatty acids, proteins and manganese and/or molybden for improving membrane composition
EA200700886A1 (ru) Соединение тиадиазола и его применение
WO2007008463A3 (en) Anti-ctla-4 antibody and cpg-motif-containing synthetic oligodeoxynucleotide combination therapy for cancer treatment
EA200900896A1 (ru) Соединения-агонисты гетероциклических рецепторов (варианты), фармацевтическая композиция на их основе, способ лечения диабета и метаболических расстройств, способ стимулирования выработки инсулина (варианты) и способы снижения уровня глюкозы и триглицеридов в крови посредством указанных соединений
EA200501607A1 (ru) Замещённые фенилалкановые кислоты
WO2006037031A3 (en) Formulations and methods for treatment of inflammatory diseases
EA201300124A1 (ru) Комбинированная фармацевтическая композиция и метод лечения сахарного диабета и метаболлических расстройств
WO2006008028A8 (de) Neue 6-formyl-tetrahydropteridine, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel, u.a. gegen krebs
MX351092B (es) Analogos peptidicos para tratar enfermedades y trastornos.
EA200501821A1 (ru) Фармацевтическая комбинация, содержащая модафинил и другой лекарственный препарат
WO2007097992A3 (en) Novel heterocyclic diphenyl ethers
EA200970127A1 (ru) Модулятор рецепторов глюкокортикостероидов и способы его применения
WO2008073466A3 (en) Alpha b-crystallin as a therapy for inflammation
EA200802132A1 (ru) Фармацевтические композиции, содержащие модуляторы каннабиноидного рецептора cbи модуляторы калиевых каналов
Yang et al. Metformin inhibits expression and secretion of PEDF in adipocyte and hepatocyte via promoting AMPK phosphorylation
PH12022550097A1 (en) Metallothionein antibodies and their use
WO2005092878A3 (en) Schweinfurthin analogues

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B15K Others concerning applications: alteration of classification

Free format text: PARA: INT. CL. A61K 31/425, 31/42; C07D 277/04, 263/04; A61P 3/00

Ipc: A61K 31/425 (2011.01), A61K 31/42 (2011.01), C07D

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 23/08/2016, OBSERVADAS AS CONDICOES LEGAIS.

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 17A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2613 DE 02-02-2021 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.